Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes

Molecular Biology of the Cell

Volumn 21, Issue 1, 2010, Pages 29-35

  Xu, Yiru ^a   Baker, Dustin ^a   Quan, Taihao ^a   Baldassare, Joseph J ^b   Voorhees, John J ^a   Fisher, Gary J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE KAPPA; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

ADULT; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INDUCTION; GENE KNOCKDOWN TECHNIQUES; HUMANS; KERATINOCYTES; PHOSPHOTYROSINE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 75649109715     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E09-08-0710     Document Type: Article

References (61)

1. Alonso, A., Sasin, J., Bottin, N., Fried, I., Fried, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., and Mustelin, T. (2004). Protein tyrosine phosphatases in human genome. Cell 117, 699-711.
2. Behar, M., Dalyot, I., Engelberg, D., and Levitzki, A. (2001). Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 21, 6913-6929.
3. Behrend, L., Henderson, G., and Zwacka, R. (2003). Reactive oxygen species in oncogenic transformation. Biochem. Sco. Trans. 31, 1441-1444.
4. Bierie, B., and Moses, H. (2006). TGF-beta and cancer. Cytokine Growth Factor Rev. 17, 29-40.
5. Carew, J., and Huang, P. (2002). Mitochondrial defeats in cancer. Mol. Cancer 1, 1-9.
6. Carew, J., Zhou, Y., Albitar, M., Carew, J., Keating, M., and Huang, P. (2003). Mitochondrial DNA mutations on primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17, 1437-1447.
7. Carpenter, G. (1987). Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56, 881-914.
8. Caunt, C. J., Rivers, C. A., Conway-Campbell, B. L., Norman, M. R., and McArdle, C. A. (2008). Epidermal growth factor receptor and protein kinase C signaling to ERK2, spatiotemporal regulation of ERK2 by dual specificity phosphatases. J. Biol. Chem. 283, 6241- 6252.
9. Coffey, R., Bascom, C., Sipes, N., Graves-Deal, R., Weisman, B., and Moses, H. (1988). Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol. Cell. Biol. 8, 3088-3093.
10. Copeland, W., Wachsman, J., Johnson, F., and Penta, J. (2002). Mitochondrial DNA alterations in cancer. Cancer Invest. 20, 557-569.
11. Derynck, R., Akhurst, R., and Balmain, A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129.
12. Derynck, R., Zhang, Y., and Feng, X. (1998). Smads: transcriptional activators of TGF-beta responses. Cell 95, 737-740.
13. Ernst, P. (1999). Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol. Ther. 13, 13-18.
14. Fawaz, G., Veveer, P., Squire, A., Neel, B., and Bastiaens, P. (2002). Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708-1711.
15. Fry, D., et al. (1998). Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022-12027.
16. Fry, D., Kraker, A., McMichael, A., Ambroso, L., Nelson, J., Leopold, W., Connors, R., and Bridges, A. (1994). A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093-1095.
17. Fuchs, M., Müller, T., Lerch, M., and Ullrich, A. (1996). Association of human protein-tyrosine phosphatase κ with members of the armadillo family. J. Biol. Chem. 271, 16712-16719.
18. Gebbink, M., Zondag, G., Koningstein, G., Feiken, E., Wubbolts, R., and Moolenaar, W. (1995). Cell surface expression of receptor protein tyrosine phosphatase RPTP-μ is regulated by cell-cell contact. J. Cell Biol. 268, 16101-16104.
19. Gomis, R., Alarson, C., Nadal, C., Van Poznak, C., and Massague, J. (2006). C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10, 203-214.
20. Gruppuso, P., Mikumo, R., Brautigan, D., and Braun, L. (1991). Growth arrest induced by transforming growth factor beta 1 is accompanied by protein phosphatase activation in human keratinocytes. J. Biol. Chem. 266, 3444-3448.
21. Hannon, G., and Beach, D. (1994). p15INK4B is potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261.
22. Heldin, C., Miyazono, K., and ten Dijke, P. (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
23. Hlavata, L., Aguilaniu, H., Pichova, A., and Nystrom, T. (2003). The oncogenic RAS2(val19) mutation locks respiration, independently of PKA, in a mode prone to generate ROS. EMBO J. 22, 3337-3345.
24. Hussain, S., Hofseth, L., and Harris, C. (2003). Radical causes of cancer. Nat. Rev. Cancer 3, 276-285.
25. Inman, G., Nicolas, F., Callahan, J., Harling, J., Gaster, L., Rieth, A., Laping, N., and Hill, C. (2002). SB-431542 is a potent and specific inhibitor or transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK 5, and ALK7. Mol. Pharmacol. 62, 65-74.
26. Jorissen, R., Walker, F., Pouliot, N., Gearrett, T., Ward, C., and Burgess, A. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284, 31-53.
27. Kumimoto, H., Yamane, Y., Nishimoto, Y., Fukami, H., Shinoda, M., Hatooka, S., and Ishizaki, K. (2004). Frequent somatic mutations of mitochondrial DNA in esophageal squamous cell carcinoma. Int. J. Cancer 108, 228-231.
28. Massague, J. (1998). TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791.
29. Massague, J. (2008). TGF-beta in cancer cells. Cell 134, 215-230.
30. Massague, J., Blain, S., and Lo, R. (2000). TGF-beta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
31. McAndrew, P., Frostholm, A., White, R., Rotter, A., and Burghes, A. (1998). Identification an characterization of RPTP rho, a novel RPTP mu/kappa-like receptor protein tyrosine phosphatase whose expression is restricted to the central nervous system. Brain Res. Mol. Brain Res. 56, 9-21.
32. Mendelsohn, J., and Baselga, J. (2003). Status of epidermal growth factor receptor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799.
33. Moses, H., Yang, E., and Pientenpol, J. (1990). TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63, 245-247.
34. Moustakas, A., Pardali, K., Gaal, A., and Heldin, C. (2002). Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol. Lett. 82, 85-91.
35. Nakamura, M., Kishi, M., Sakakim, T., Hashimoto, H., Nakase, H., Sihimada, K., Ishida, E., and Konishi, N. (2003). Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 63, 737-741.
36. Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M., Carotenuto, A., De Fei, G., Caponigro, F., and Salomon, D. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16.
37. Novellino, L., et al. (2003). Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J. Immunol. 170, 6363-6370.
38. Orlando, V., Strutt, H., and Paro, R. (1997). Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods 11, 205-214.
39. Prenzel, N., Fischer, O., Streit, S., Hart, S., and Ullrich, A. (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Cancer 8, 11-31.
40. Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Gene Dev. 9, 1831-1845.
41. Rizzino, A. (1988). Transforming growth factor-beta: Multiple effects on cell differentiation and extracellular matrices. Dev. Biol. 130, 411-422.
42. Salmeen, A., Andersen, J., Myers, M., Meng, T., Hinks, J., Tonks, N., and Barford, D. (2003). Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423, 769-773.
43. Sap, J., Jiang, J.-P., Friedlander, D., Grument, M., and Schlessinger, J. (1994). Receptor tyrosine phosphate R-PTP-κ mediates homophilic binding. Mol. Cell. Biol. 14, 1-9.
44. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
45. Seoane, J., Le, H., Anderson, S., and Massague, J. (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and gliblastoma cell proliferation. Cell 117, 211-223.
46. Shipley, G., Pittelkow, M., Wille, J., Jr., Scott, R., and Moses, H. (1986). Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res. 46, 2068-2071.
47. Tiganis, T., Kemp, B., and Tonks, N. (1999). The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling. J. Biol. Chem. 274, 27768-27775.
48. Tonks, N. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7, 833-846.
49. Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T., Hampton, G., and Wahl, G. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031-1144.
50. van Montfort, R., Congreve, M., Tisi, D., Carr, R., and Jhoti, H. (2003). Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 423, 773-777.
51. Wakefield, L., and Roberts, A. (2002). TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29.
52. Wang, S., Wu, F., Shin, I., Qu, S., and Arteaga, C. (2005). Transforming growth factor β(TGF-β)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-β function. Mol. Cell. Biol. 25, 4703-4715.
53. Wang, X. (2001). Role of TGF-beta signaling in skin carcinogenesis. Microsc Res. Tech. 52, 420-429.
54. Wang, Z., Wang, M., Lazo, J., and Carr, B. (2002). Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J. Biol. Chem. 277, 19470-19475.
55. Xu, Y., and Fisher, G. (2005). Ultraviolet (UV) light irradiation induced signal transduction in skin photoaging. J. Dermatol. Sci. Suppl. 1, S1-S8.
56. Xu, Y., Shao, Y., Voorhees, J., and Fisher, G. (2006a). Oxidative inhibition of receptor-type protein-tyrosine phosphatase κ by ultraviolet irradiation activates epidermal growth factor receptor in human keratinocytes. J. Biol. Chem. 291, 27389-27397.
57. Xu, Y., Tan, L., Grachtchouk, V., Voorhees, J., and Fisher, G. (2005). Receptor-type protein-tyrosine phosphatase-κ regulates epidermal growth factor receptor function. J. Biol. Chem. 280, 42694-42700.
58. Xu, Y., Voorhees, J., and Fisher, G. (2006b). Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells. Am. J. Pathol. 169, 823-830.
59. Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwani, H., Sugamura, K., Miyazono, K., and Kato, M. (2002). c-myc is a downstream target of the Samd pathway. J. Biol. Chem. 277, 854-861.
60. Yang, Y., Gil, M., Byun, S., Choi, I., Pyun, K., and Ha, H. (1996). Transforming growth factor-beta1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-kappa gene expression. Biochem. Biophys. Res. Comm. 228, 807-812.
61. Zondag, G., Koningstein, G., Jiang, J.-P., Sap, J., Moolenaar, W., and Gebbink, M. (1995). Homophilic interactions mediated by receptor tyrosine phosphatases μ and κ. A critical role for the novel extracellular MAM domain. J. Biol. Chem. 270, 14247-14250.